Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dolby Laboratories, Inc.DLB · Entity 2518 | Director · President and CEO | February 05, 2026 | February 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dolby Laboratories, Inc.
Report date February 05, 2026 · Filed February 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.62 · Expires 2035-12-15 | Direct | 145,252 |
Reported balance
After 2026-02-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-05 · Gift · Disposed 145,252 · Balance 145,252 F1: Effective February 5, 2026, the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. This transfer is exempt from Section 16(b) by virtue of Rule 16b-5. F2: This option was granted for a total of 145,252 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2025, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.62 · Expires 2035-12-15 | IndirectBy a trust | 145,252 |
Reported balance
After 2026-02-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-05 · Gift · Acquired 145,252 · Balance 145,252 F1: Effective February 5, 2026, the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. This transfer is exempt from Section 16(b) by virtue of Rule 16b-5. F2: This option was granted for a total of 145,252 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2025, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. F3: By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 |
Filing footnotes · ownership attribution and instrument terms
F1: Effective February 5, 2026, the Reporting Person transferred this option to a revocable trust for no consideration, for estate planning purposes. This transfer is exempt from Section 16(b) by virtue of Rule 16b-5.
F2: This option was granted for a total of 145,252 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2025, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter.
F3: By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2017 Filed Dec 19, 2017 20:59 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Tax withholdingClass A Common Stock | 7,050 | $62.32 | $439,356.00 |
DisclosureSEC source: 0001209191-17-066575 · doc4.xml · nonDerivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,828 F1 · kind: In accordance with Rule 16b-3, shares reported as disposed of were withheld by the Issuer and not issued to the reporting person in order to cover withholding taxes incidental to the vesting of restricted stock units. F5 · balance_after: Shares held following the reported transactions include 114,828 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 20:59 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GrantEmployee Stock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $62.32 | $0.00 |
DisclosureSEC source: 0001209191-17-066575 · doc4.xml · derivative · entry 9 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Class A Common Stock · 180,000 shares Expires 2027-12-15 F9 · derivative.exercise_date: This option was granted for a total of 180,000 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2017, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 20:59 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GrantPerformance-Based Stock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $62.32 | $0.00 |
DisclosureSEC source: 0001209191-17-066575 · doc4.xml · derivative · entry 8 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Class A Common Stock · 90,000 shares Expires 2024-12-15 F8 · derivative.exercise_date: The vesting of this performance-based stock option ("PSO") award is dependent upon achievement of performance criteria measured during a three-year performance period beginning on December 15, 2017 and ending December 15, 2020. The number of shares reported is at the target award amount. The reporting person may potentially earn from 0% to 125% of the target award amount based on total shareholder return at the end of the three-year performance period. The actual PSO award earned shall vest immediately upon certification by the Company's Compensation Committee of the achievement of the performance criteria, following the end of the three-year performance period. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 20:59 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GrantClass A Common Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066575 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,338 F3 · acquired: Award represents a total of 45,000 restricted stock units granted under the terms of the Issuer's 2005 Stock Plan. Under the terms of the restricted stock unit grant agreement, 1/4 of the total number of units shall vest on each anniversary of December 15, 2017. Each unit represents a contingent right to receive one share of the Issuer's Class A Common Stock upon vesting. F4 · balance_after: Shares held following the reported transactions include 128,338 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 20:59 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Tax withholdingClass A Common Stock | 18,219 | $60.99 | $1,111,176.81 |
DisclosureSEC source: 0001209191-17-066575 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,338 F1 · kind: In accordance with Rule 16b-3, shares reported as disposed of were withheld by the Issuer and not issued to the reporting person in order to cover withholding taxes incidental to the vesting of restricted stock units. F2 · balance_after: Shares held following the reported transactions include 83,338 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest. Read SEC document |
| November 02, 2017 Filed Nov 2, 2017 21:14 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 10,000 | $58.38 | $583,793.00 |
DisclosureSEC source: 0001209191-17-059019 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 77,895 F1 · price: This transaction was executed in multiple trades at prices ranging from $57.99 to $58.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 16:32 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $28.66 | $0.00 |
DisclosureSEC source: 0001209191-17-057639 · doc4.xml · derivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 12,655 Underlying: Class A Common Stock · 30,000 shares Expires 2019-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted for a total of 134,757 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of March 16, 2009, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 16:32 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 30,000 | $60.00 | $1,800,000.00 |
DisclosureSEC source: 0001209191-17-057639 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 87,895 Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 16:32 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 30,000 | $28.66 | $859,800.00 |
DisclosureSEC source: 0001209191-17-057639 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 117,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 16:41 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $28.66 | $0.00 |
DisclosureSEC source: 0001209191-17-053000 · doc4.xml · derivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 42,655 Underlying: Class A Common Stock · 45,000 shares Expires 2019-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted for a total of 134,757 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of March 16, 2009, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 16:41 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 25,000 | $57.54 | $1,438,532.50 |
DisclosureSEC source: 0001209191-17-053000 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 87,895 F2 · price: This transaction was executed in multiple trades at prices ranging from $57.50 to $57.705. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 16:41 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 20,000 | $55.10 | $1,102,062.00 |
DisclosureSEC source: 0001209191-17-053000 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 112,895 F1 · price: This transaction was executed in multiple trades at prices ranging from $55.00 to $55.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 16:41 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 45,000 | $28.66 | $1,289,700.00 |
DisclosureSEC source: 0001209191-17-053000 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 132,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2017 Filed Aug 3, 2017 18:42 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 10,000 | $51.79 | $517,883.00 |
DisclosureSEC source: 0001209191-17-047517 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 87,895 F1 · price: This transaction was executed in multiple trades at prices ranging from $51.37 to $52.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 02, 2017 Filed May 3, 2017 16:36 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 10,000 | $51.33 | $513,326.00 |
DisclosureSEC source: 0001209191-17-029686 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 97,895 F1 · price: This transaction was executed in multiple trades at prices ranging from $51.09 to $51.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 29, 2017 Filed Mar 31, 2017 16:54 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 10,000 | $52.51 | $525,057.00 |
DisclosureSEC source: 0001209191-17-023889 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 107,895 F1 · price: This transaction was executed in multiple trades at prices ranging from $52.50 to $52.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 20:42 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 5,000 | $50.00 | $250,024.00 |
DisclosureSEC source: 0001209191-17-017011 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 117,895 F1 · price: This transaction was executed in multiple trades at prices ranging from $50 to $50.015. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 01, 2017 Filed Mar 2, 2017 20:41 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 10,000 | $47.88 | $478,768.00 |
DisclosureSEC source: 0001209191-17-017007 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 122,895 F1 · price: This transaction was executed in multiple trades at prices ranging from $47.71 to $48.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 22, 2016 Filed Dec 22, 2016 19:35 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 2,943 | $46.10 | $135,666.41 |
DisclosureSEC source: 0001209191-16-156605 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 132,895 F3 · price: This transaction was executed in multiple trades at prices ranging from $45.95 to $46.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 21, 2016 Filed Dec 22, 2016 19:35 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Tax withholdingClass A Common Stock | 7,136 | $46.30 | $330,396.80 |
DisclosureSEC source: 0001209191-16-156605 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,251 F1 · kind: In accordance with Rule 16b-3, shares reported as disposed of were withheld by the Issuer and not issued to the reporting person in order to cover withholding taxes incident to the vesting of restricted stock units. F2 · balance_after: Shares held following the reported transactions include 118,251 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest. Read SEC document |
| December 19, 2016 Filed Dec 19, 2016 19:17 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 2,907 | $45.94 | $133,559.21 |
DisclosureSEC source: 0001209191-16-156017 · doc4.xml · nonDerivative · entry 7 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 129,299 F7 · price: This transaction was executed in multiple trades at prices ranging from $45.75 to $46.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 19:17 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 2,504 | $45.71 | $114,450.08 |
DisclosureSEC source: 0001209191-16-156017 · doc4.xml · nonDerivative · entry 6 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 Disclosed balance after: 132,206 F6 · price: This transaction was executed in multiple trades at prices ranging from $45.50 to $45.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 19:17 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Tax withholdingClass A Common Stock | 7,049 | $45.86 | $323,267.14 |
DisclosureSEC source: 0001209191-16-156017 · doc4.xml · nonDerivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,926 F3 · kind: In accordance with Rule 16b-3, shares reported as disposed of were withheld by the Issuer and not issued to the reporting person in order to cover withholding taxes incident to the vesting of restricted stock units. F5 · balance_after: Shares held following the reported transactions include 131,926 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 19:17 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GrantEmployee Stock Option (Right to Buy) · Derivative | 194,399 | $0.00 Strike: $45.50 | $0.00 |
DisclosureSEC source: 0001209191-16-156017 · doc4.xml · derivative · entry 9 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,399 Underlying: Class A Common Stock · 194,399 shares Expires 2026-12-15 F9 · derivative.exercise_date: This option was granted for a total of 194,399 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vests on the first anniversary of December 15, 2016, the vesting commencement date, and the balance of the shares in equal monthly installments over the next 36 months thereafter. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 19:17 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GrantPerformance-Based Stock Option (Right to Buy) · Derivative | 97,199 | $0.00 Strike: $45.50 | $0.00 |
DisclosureSEC source: 0001209191-16-156017 · doc4.xml · derivative · entry 8 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,199 Underlying: Class A Common Stock · 97,199 shares Expires 2023-12-15 F8 · derivative.exercise_date: The vesting of this performance-based stock option ("PSO") award is dependent upon achievement of performance criteria measured during a three-year performance period beginning on December 15, 2016 and ending December 15, 2019. The number of shares reported is at the target award amount. The reporting person may potentially earn from 0% to 125% of the target award amount based on total shareholder return at the end of the three-year performance period. The actual PSO award earned shall vest immediately upon certification by the Company's Compensation Committee of the achievement of the performance criteria, following the end of the three-year performance period. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 19:17 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Tax withholdingClass A Common Stock | 12,146 | $45.50 | $552,643.00 |
DisclosureSEC source: 0001209191-16-156017 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,435 F3 · kind: In accordance with Rule 16b-3, shares reported as disposed of were withheld by the Issuer and not issued to the reporting person in order to cover withholding taxes incident to the vesting of restricted stock units. F4 · balance_after: Shares held following the reported transactions include 145,435 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 19:17 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | GrantClass A Common Stock | 46,551 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-156017 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,710 F1 · acquired: Award represents a total of 46,551 restricted stock units granted under the terms of the Issuer's 2005 Stock Plan. Under the terms of the restricted stock unit grant agreement, 1/4 of the total number of units shall vest on each anniversary of December 15, 2016. Each unit represents a contingent right to receive one share of the Issuer's Class A Common Stock upon vesting. F2 · balance_after: Shares held following the reported transactions include 168,710 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest. Read SEC document |
| October 10, 2016 Filed Oct 11, 2016 16:34 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 152 | $0.00 Strike: $28.66 | $0.00 |
DisclosureSEC source: 0001209191-16-145578 · doc4.xml · derivative · entry 9 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 87,655 Underlying: Class A Common Stock · 152 shares Expires 2019-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted for a total of 134,757 shares of Class A Common Stock and became fully vested on March 16, 2013. Read SEC document |
| October 10, 2016 Filed Oct 11, 2016 16:34 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 152 | $55.00 | $8,360.00 |
DisclosureSEC source: 0001209191-16-145578 · doc4.xml · nonDerivative · entry 6 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 117,121 Read SEC document |
| October 10, 2016 Filed Oct 11, 2016 16:34 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 152 | $28.66 | $4,356.32 |
DisclosureSEC source: 0001209191-16-145578 · doc4.xml · nonDerivative · entry 5 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 117,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2016 Filed Oct 11, 2016 16:34 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,701 | $0.00 Strike: $28.66 | $0.00 |
DisclosureSEC source: 0001209191-16-145578 · doc4.xml · derivative · entry 8 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 87,807 Underlying: Class A Common Stock · 1,701 shares Expires 2019-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted for a total of 134,757 shares of Class A Common Stock and became fully vested on March 16, 2013. Read SEC document |
| October 07, 2016 Filed Oct 11, 2016 16:34 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 1,701 | $55.00 | $93,555.00 |
DisclosureSEC source: 0001209191-16-145578 · doc4.xml · nonDerivative · entry 4 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 117,121 Read SEC document |
| October 07, 2016 Filed Oct 11, 2016 16:34 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 1,701 | $28.66 | $48,750.66 |
DisclosureSEC source: 0001209191-16-145578 · doc4.xml · nonDerivative · entry 3 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 118,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 06, 2016 Filed Oct 11, 2016 16:34 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,249 | $0.00 Strike: $28.66 | $0.00 |
DisclosureSEC source: 0001209191-16-145578 · doc4.xml · derivative · entry 7 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 89,508 Underlying: Class A Common Stock · 20,249 shares Expires 2019-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted for a total of 134,757 shares of Class A Common Stock and became fully vested on March 16, 2013. Read SEC document |
| October 06, 2016 Filed Oct 11, 2016 16:34 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | SaleClass A Common Stock | 20,249 | $55.00 | $1,113,741.57 |
DisclosureSEC source: 0001209191-16-145578 · doc4.xml · nonDerivative · entry 2 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 117,121 F1 · price: This transaction was executed in multiple trades at prices ranging from $55 to $55.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| October 06, 2016 Filed Oct 11, 2016 16:34 UTC | Dolby Laboratories, Inc. DLB · Entity 2518 | Exercise / conversionClass A Common Stock | 20,249 | $28.66 | $580,336.34 |
DisclosureSEC source: 0001209191-16-145578 · doc4.xml · nonDerivative · entry 1 YEAMAN KEVIN J · CIK 0001200469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kevin and Rachel Yeaman Family Trust, dated May 14, 2009 Disclosed balance after: 137,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.